Results 81 to 90 of about 20,079 (290)

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Varenicline for smoking cessation: Is it a heartbreaker? [PDF]

Canadian Medical Association Journal, 2011
See related research article by Singh and colleagues on page [1359][1] and at [www.cmaj.ca/lookup/doi/10.1503/cmaj.110218][2] and related letters on page [1404][3]. In this issue of CMAJ , Singh and colleagues[1][4] present a meta-analysis assessing the risk of serious adverse cardiovascular ...
openaire   +3 more sources

Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations

Current Medical Research and Opinion, 2020
Objective: Varenicline, a selective partial agonist of the α4β2 nicotinic acetylcholine receptor, is a smoking cessation pharmacotherapy that more than doubles the chance of quitting smoking at 6 months compared with placebo. This article reviews salient
S. Tonstad, C. Arons, H. Rollema, I. Berlin, P. Hajek, K. Fagerström, C. Els, T. McRae, C. Russ   +8 more
semanticscholar   +1 more source

Risk of Stroke in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Cohort Study of 183,504 Subjects

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Major psychiatric disorder, including schizophrenia, bipolar disorder, and major depressive disorder, has been individually associated with increased risk of stroke. However, few studies have directly compared the stroke risk across these diagnostic groups within a unified cohort framework while accounting for stroke subtypes and ...
Mao‐Hsuan Huang, Chih‐Ming Cheng, Ju‐Wei Hsu, Ya‐Mei Bai, Tung‐Ping Su, Cheng‐Ta Li, Shih‐Jen Tsai, Yee‐Lam E. Chan, Mu‐Hong Chen   +8 more
wiley   +1 more source

Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink

Health Technology Assessment, 2020
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line treatments for smoking cessation are nicotine replacement therapy and varenicline.
Neil M Davies, Amy E Taylor, Gemma MJ Taylor, Taha Itani, Tim Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas   +8 more
doaj   +1 more source

Smoking cessation in severe mental ill health : what works? an updated systematic review and meta-analysis [PDF]

, 2017
BACKGROUND: People with severe mental ill health are more likely to smoke than those in the general population. It is therefore important that effective smoking cessation strategies are used to help people with severe mental ill health to stop smoking ...
A Baker, A Baker, AE Evins, AE Evins, AE Evins, AE Evins, AH Weinberger, AL Baker, B O'Brien, BS Wu, C Bullen, C McDonald, E Ratschen, E Weiner, E Weiner, Emily Peckham, Garry Tew, GW Dalack, HK Chen, J Hartmann-Boyce, JM Williams, JM Williams, JM Williams, JW Tidey, KN Chengappa, KR Fontaine, L Banham, Liz Cook, ML Steinberg, ML Steinberg, Q Wu, RC Smith, RM Anthenelli, S Brown, S Fatemi, S Gilbody, Sally Brabyn, SE Adkison, Simon Gilbody, SM Gallagher, TP George, TP George, TP George, VC Wing   +43 more
core   +1 more source

An update of a systematic review and meta‐analyses exploring flavours in intervention studies of e‐cigarettes for smoking cessation

Addiction, Volume 120, Issue 4, Page 770-778, April 2025.
Abstract Aims To determine patterns of e‐cigarette flavour use (sweet, tobacco, menthol/mint) in interventional studies of e‐cigarettes for stopping smoking, and to estimate associations between flavours and smoking/vaping outcomes. Methods Update of secondary data analyses, including meta‐analyses subgrouped by flavour provision and narrative ...
Nicola Lindson, Jonathan Livingstone‐Banks, Ailsa R. Butler, David T. Levy, Phoebe Barnett, Annika Theodoulou, Caitlin Notley, Nancy A. Rigotti, Yixian Chen, Jamie Hartmann‐Boyce   +9 more
wiley   +1 more source

Varenicline overdose in a teenager [PDF]

Clinical Toxicology, 2009
Varenicline (Chantix®) is a selective partial agonist of α4β2 nicotinic acetylcholine receptor subtypes. It is approved in the United States to aid with smoking cessation.
Amy Joy Hedlund, Lee Cantrell, Molly Broderick, Nilofar Shah   +3 more
openaire   +2 more sources

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source